Probing the β2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists

被引:227
作者
Swaminath, G [1 ]
Deupi, X [1 ]
Lee, TW [1 ]
Zhu, W [1 ]
Thian, FS [1 ]
Kobilka, TS [1 ]
Kobilka, B [1 ]
机构
[1] Stanford Univ, Sch Med, Dept Mol & Cellular Physiol, Palo Alto, CA 94305 USA
关键词
D O I
10.1074/jbc.M502352200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The beta(2) adrenergic receptor (beta(2)AR) is a prototypical family A G protein-coupled receptor (GPCR) and an excellent model system for studying the mechanism of GPCR activation. The beta(2)AR agonist binding site is well characterized, and there is a wealth of structurally related ligands with functionally diverse properties. In the present study, we use catechol (1,2-benzenediol, a structural component of catecholamine agonists) as a molecular probe to identify mechanistic differences between beta(2)AR activation by catecholamine agonists, such as isoproterenol, and by the structurally related non-catechol partial agonist salbutamol. Using biophysical and pharmacologic approaches, we show that the aromatic ring of salbutamol binds to a different site on the beta(2)AR than the aromatic ring of catecholamines. This difference is important in receptor activation as it has been hypothesized that the aromatic ring of catecholamines plays a role in triggering receptor activation through interactions with a conserved cluster of aromatic residues in the sixth transmembrane segment by a rotamer toggle switch mechanism. Our experiments indicate that the aromatic ring of salbutamol does not activate this mechanism either directly or indirectly. Moreover, the non-catechol ring of partial agonists does not interact optimally with serine residues in the fifth transmembrane helix that have been shown to play an important role in activation by catecholamines. These results demonstrate unexpected differences in binding and activation by structurally similar agonists and partial agonists. Moreover, they provide evidence that activation of a GPCR is a multistep process that can be dissected into its component parts using agonist fragments.
引用
收藏
页码:22165 / 22171
页数:7
相关论文
共 30 条
[1]   β-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors [J].
Azzi, M ;
Charest, PG ;
Angers, S ;
Rousseau, G ;
Kohout, T ;
Bouvier, M ;
Piñeyro, G .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (20) :11406-11411
[2]  
Ballesteros JA, 1995, Methods Neurosci, V25, P366, DOI [DOI 10.1016/S1043-9471(05)80049-7, 10.1016/S1043-9471(05)80049-7]
[3]   A graph-theory algorithm for rapid protein side-chain prediction [J].
Canutescu, AA ;
Shelenkov, AA ;
Dunbrack, RL .
PROTEIN SCIENCE, 2003, 12 (09) :2001-2014
[4]  
Case D.A., 2004, AMBER 8
[5]   Mutation of a single TMVI residue, Phe282, in the β2-adrenergic receptor results in structurally distinct activated receptor conformations [J].
Chen, SH ;
Lin, F ;
Xu, M ;
Riek, RP ;
Novotny, J ;
Graham, RM .
BIOCHEMISTRY, 2002, 41 (19) :6045-6053
[6]   Induced-fit mechanism for catecholamine binding to the β2-adrenergic receptor [J].
Del Carmine, R ;
Molinari, P ;
Sbraccia, M ;
Ambrosio, C ;
Costa, T .
MOLECULAR PHARMACOLOGY, 2004, 66 (02) :356-363
[7]   Modeling of loops in protein structures [J].
Fiser, A ;
Do, RKG ;
Sali, A .
PROTEIN SCIENCE, 2000, 9 (09) :1753-1773
[8]   Agonist-induced conformational changes in the G-protein-coupling domain of the β2 adrenergic receptor [J].
Ghanouni, P ;
Steenhuis, JJ ;
Farrens, DL ;
Kobilka, BK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (11) :5997-6002
[9]   Functionally different agonists induce distinct conformations in the G protein coupling domain of the β2 adrenergic receptor [J].
Ghanouni, P ;
Gryczynski, Z ;
Steenhuis, JJ ;
Lee, TW ;
Farrens, DL ;
Lakowicz, JR ;
Kobilka, BK .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (27) :24433-24436
[10]   Agonist binding: A multistep process [J].
Kobilka, B .
MOLECULAR PHARMACOLOGY, 2004, 65 (05) :1060-1062